Overview

A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer

Status:
Unknown status

Trial end date:
2018-03-01

Target enrollment:

Participant gender:

Summary

Nimotuzumab is a humanized monoclonal antibody against epidermal growth factor receptor (EGFR). Clinical trials are ongoing globally to evaluate Nimotuzumab in different indications. Nimotuzumab has been approved to treat squamous cell carcinoma of head and neck (SCCHN), glioma and nasopharyngeal carcinoma in different countries.The clinical phase Ⅲ trial designed to assess overall survival（OS）of the combination of Nimotuzumab administered concurrently with Gemcitabine in patients with RAS wild type of locally advanced or metastatic pancreatic cancer

Phase:

Phase 3

Details

Lead Sponsor:

Biotech Pharmaceutical Co., Ltd.

Collaborators:

Fudan University
NanJing PLA 81 Hospital

Treatments:

Gemcitabine
Nimotuzumab